Talphera's Research Enhances Anticoagulation Strategies in Critical Kidney Care
- Talphera will present two abstracts at the 31st Annual International Conference on Advances in Critical Care Nephrology in 2026.
- The NEPHRO-CRRT study examines nafamostat as a safe anticoagulant for CRRT patients with high bleeding risk.
- Talphera's research aims to enhance anticoagulation strategies, improving outcomes for patients requiring Continuous Renal Replacement Therapy.
Talphera Advances Critical Anticoagulation Research for Renal Therapy
Talphera, Inc., a specialty pharmaceutical company located in San Mateo, California, is making significant strides in critical care nephrology with the acceptance of two abstracts for presentation at the upcoming 31st Annual International Conference on Advances in Critical Care Nephrology: AKI & CRRT 2026. Scheduled for March 29 to April 2, 2026, in San Diego, this conference serves as a platform for sharing valuable research innovations aimed at improving kidney care. The highlighted presentations delve into the urgent need for safe anticoagulation options during Continuous Renal Replacement Therapy (CRRT), addressing a pressing challenge in managing patients with a heightened bleeding risk.
The first presentation introduces the NEPHRO-CRRT study, a randomized, placebo-controlled, multi-center trial that examines the safety and efficacy of nafamostat, a regional anticoagulant. This study specifically targets patients undergoing CRRT who cannot tolerate traditional anticoagulants like heparin or possess an elevated risk of bleeding. Currently in the recruitment phase, the NEPHRO-CRRT study aims to gather data that could pave the way for nafamostat's approval in the United States. Given that nafamostat has been safely utilized in Japan and South Korea for over thirty years, the potential for its use in U.S. clinical settings represents a significant advancement in renal therapy protocols.
The second abstract presented by Talphera focuses on nafamostat's pharmacokinetics in a porcine model of acute kidney injury (AKI) paired with CRRT. This research reveals that over 95% of nafamostat is eliminated by the hemofilter when administered prior to filtration, thus optimizing anticoagulation strategies. The study is particularly noteworthy for its targeted activation of clotting time (ACT) parameters, set between 175 to 225 seconds. This careful management minimizes adverse systemic changes in ACT, offering a more refined approach to anticoagulation during CRRT. Dr. Shakil Aslam, Chief Medical Officer of Talphera, articulates confidence in nafamostat’s potential, reinforcing the company’s commitment to advancing clinical research in this critical healthcare domain.
Talphera's ongoing experiments and trials align with the broader industry trend toward safer anticoagulation methods in critical care environments. By presenting its research at this notable conference, the company not only contributes to scientific knowledge but also highlights its role as an innovator in nephrology. As Talphera navigates its research trajectory, the implications of these studies could mark a transformative era in the management of patients requiring CRRT.
In addition to this research, Talphera remains focused on its strategic objectives to develop solutions that meet acute medical needs. By enhancing anticoagulation strategies during CRRT, the company seeks to alleviate concerns regarding bleeding risks, ultimately aiming for improved patient outcomes in critical care settings. This initiative reinforces Talphera's position as a leader in specialty pharmaceuticals across the renal therapy landscape.